Sign Out
Type 1 diabetes; not recommended.
Diabetic ketoacidosis; not recommended.
Galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption; use not recommended, as product contains lactose.
Use is not recommend in patients with preexisting hepatic impairment, including patients with a pre-treatment ALT or AST >2.5x the upper limit of normal.
Hepatic dysfunction (e.g., hepatitis) has been reported; monitoring recommended and discontinuation may be necessary.
Discontinue therapy if ALT or AST is persistently >3 times the upper limit of normal or if jaundice or other signs of hepatic dysfunction occur. Do not reinitiate therapy, even after hepatic function normalizes.
Renal: Moderate or severe renal (CrCl <50 mL/min), or ESRD; dosage adjustment necessary.
Use in Children: Safety and efficacy not established in pediatric patients younger than 18 years.
Continue with Google